Risk factors for breakthrough candidemia

被引:79
作者
Nucci, M
Colombo, AL
机构
[1] Univ Fed Rio de Janeiro, Univ Hosp, BR-21941590 Rio De Janeiro, Brazil
[2] Univ Fed Sao Paulo, Univ Hosp, BR-04037002 Sao Paulo, Brazil
关键词
D O I
10.1007/s10096-002-0697-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In order to assess the risk factors for breakthrough candidemia (candidemia occurring in patients receiving at least 3 days of systemic fluconazole or amphotericin B), 270 cases of candidemia occurring in two tertiary hospitals were analyzed. Using multivariate analysis, profound neutropenia (<100/mm(3)) (odds ratio [OR], 9.14), use of corticosteroids (OR, 3.17), and heavy antibiotic exposure (previous use of 2 or more antibiotics for at least 14 days) (OR, 2.93) were identified as risk factors. Neither the susceptibility of the isolates nor the presence of a catheter was found to be a risk factor. These data suggest that gastrointestinal colonization plays a major role in the development of breakthrough candidemia.
引用
收藏
页码:209 / 211
页数:3
相关论文
共 15 条
[1]   Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer [J].
Blumberg, EA ;
Reboli, AC .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (03) :462-466
[2]   Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies [J].
Girmenia, C ;
Martino, P ;
Cassone, A .
BLOOD, 1996, 87 (02) :838-839
[3]   EXPERIMENTAL DISSEMINATED CANDIDIASIS .2. ADMINISTRATION OF GLUCOCORTICOSTEROIDS, SUSCEPTIBILITY TO INFECTION, AND IMMUNITY [J].
HURLEY, DL ;
BALOW, JE ;
FAUCI, AS .
JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (04) :393-398
[4]  
KINSMAN OS, 1989, MYCOSES, V32, P664, DOI 10.1111/j.1439-0507.1989.tb02199.x
[5]   Ceftriaxone and dexamethasone affecting yeast gut flora in experimental mice [J].
Maraki, S ;
Hajiioannou, I ;
Anatoliotakis, N ;
Plataki, M ;
Chatzinikolaou, I ;
Zoras, O ;
Tselentis, Y ;
Samonis, G .
JOURNAL OF CHEMOTHERAPY, 1999, 11 (05) :363-366
[6]   Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole [J].
Marr, KA ;
Seidel, K ;
White, TC ;
Bowden, RA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :309-316
[7]  
MYEROWITZ RL, 1981, ARCH PATHOL LAB MED, V105, P138
[8]  
NAKAGAWA Z, 1998, 40 INT S ANT AG CHEM
[9]  
*NAT COMM CLIN LAB, 1997, M27A NAT COMM CLIN L, V17, P1
[10]   Breakthrough candidemia in neutropenic patients [J].
Nucci, M ;
Colombo, AL ;
Spector, N ;
Velasco, E ;
Martins, CA ;
Pulcheri, W .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :275-276